Dr James Rushworth, Senior Scientist II, will join the panel discussion on "Is a platform where it is at? Do I need one to get investment?" The panel will explore the benefits and drawbacks of adopting a platform strategy for biotech companies seeking investment and managing a broad IP portfolio. Dr Rushworth will share his insights and experiences in building Sixfold Bio's IP patent portfolio.

Dr Tina Flatau, CBO at Sixfold Bioscience, will participate in the panel discussion on "How do you grow your business in a tough environment?" The panel will focus on strategies for navigating challenging business environments and growing successful biotech companies. Dr Flatau will share her experiences in developing partnerships and allocating capital to advance Sixfold Bioscience's R&D programs.

"We are excited to participate in these panels at the Biointegrates Conference," said Dr Rushworth. "It is an excellent opportunity to share our insights and experiences in building a successful biotech IP portfolio for a platform technology."

The Biointegrates conference is a premier event for the life science industry, bringing together industry leaders, investors, and innovators to discuss the latest trends and developments in biotech. The conference will feature presentations, panel discussions, and networking opportunities.

Sixfold Bioscience is a venture-backed preclinical-stage biotechnology company, founded in 2017, based at the Translation & Innovation Hub in White City, London. Sixfold develops programmable drug delivery systems, with a current focus on siRNA and ASO.

Sixfold’s RNA delivery platform, Mergo®, was conceived by co-founders Dr Perdrix Rosell and Dr George Foot, who were left frustrated by current delivery systems that were either too toxic or faced complex engineering challenges. The Company’s differentiated approach is based on engineering biocompatible nano-architectures with precise chemical profiles that guide the RNA to selected organs.